Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Convergence is going virtual. Join the brightest minds in regulatory online to gain the latest knowledge in the field in an all-virtual experience with workshops, one-on-one expert sessions, and networking communities.
This year, our European regulatory community will converge online with a fully virtual program that will allow attendees to experience Euro Convergence live online from the safety and comfort of their homes.
RAPS' “how to” guide to developing a comprehensive global regulatory strategy for all types of medical devices. Updated September 2020.
The last exam window of 2020 is currently open. Register by 8 October to take the RAC exam this autumn.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.
Posted 10 December 2013
The former CEO of a now-disgraced manufacturer of breast implants that was accused of willfully misleading regulatory officials for years has been found guilty by a French court and sentenced to four years in Jail.
Jean-Claude Mas, former CEO of the now-defunct manufacturer Poly Implant Prothese (PIP), was accused in 2010 of distributing hundreds of thousands of breast implant products made with deficient, industrial-grade silicone without the approval of regulators.
In the midst of the crisis, regulators around the globe scrambled to determine what, if any, risks patients implanted with the devices might face. Some were concerned about higher-than-expected reports of the devices rupturing and requiring surgical revision, while others were concerned that the silicone within the devices could result in toxicities in the body.
Ultimately, most of those concerns seemed to be unwarranted. Australia's Therapeutic Goods Administration (TGA), for example, said there was "no evidence of an increased rupture rate for PIP Poly Implant Prothese silicone gel breast implants used in Australia." The UK's Medicines and Healthcare product Regulatory Agency (MHRA) said it would not-unlike Sweden-recommend getting the implants removed as a precautionary measure. And the UK's Department of Health (DOH) subsequently cleared the implants of most serious concerns, saying it found no indications that they would adversely affect long-term human health.
In October 2013, those concerns were further put to rest by the European Commission's Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR), which issued a report indicating that the chemicals within the products were safe. The committee did, however, note a higher-than-anticipated rupture rate for the implants.
According to Reutersand CNN, Mas has now been sentenced to four years and jail and ordered to pay €75,000 in penalties. Four other former executives of PIP, including the director of quality, were also sentenced to prison time ranging between 18 and 36 months.
Reuters reports that Mas will appeal the decision.
Tags: Prison, Breast Implant, PIP, France, EU
Regulatory Focus newsletters
All the biggest regulatory news and happenings.